Provided by Tiger Trade Technology Pte. Ltd.

KemPharm, Inc.

5.81
0.0000
Volume:- -
Turnover:374.33K
Market Cap:200.47M
PE:-5.72
High:5.81
Open:5.81
Low:5.81
Close:5.81
52wk High:6.92
52wk Low:4.00
Shares:34.50M
Float Shares:31.26M
Volume Ratio:- -
T/O Rate:- -
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.0159
EPS(LYR):-2.1130
ROE:-31.24%
ROA:-8.97%
PB:2.14
PE(LYR):-2.75

Loading ...

Dec 18, 2019

Major Issues Report

Current report, items 1.01, 2.03, 3.02, 3.03, 5.03, 7.01, and 9.01
Nov 21, 2019

Major Issues Report

Current report, item 3.01
Nov 14, 2019

Quarterly Report

Quarterly report [Sections 13 or 15(d)]
Nov 14, 2019

Major Issues Report

Current report, items 2.02 and 9.01
Oct 31, 2019

Major Issues Report

Current report, item 8.01
Oct 03, 2019

Major Issues Report

Current report, item 3.01
Sep 20, 2019

Major Issues Report

Current report, items 5.02, 7.01, and 9.01
Sep 04, 2019

Major Issues Report

Current report, items 1.01, 3.02, 3.03, 5.03, 7.01, and 9.01
Aug 13, 2019

Quarterly Report

Quarterly report [Sections 13 or 15(d)]
Aug 13, 2019

Major Issues Report

Current report, items 2.02 and 9.01
Jul 02, 2019

Statement Of Changes In Beneficial Ownership

Statement of changes in beneficial ownership of securities
Jul 02, 2019

Statement Of Changes In Beneficial Ownership

Statement of changes in beneficial ownership of securities
Jul 02, 2019

Statement Of Changes In Beneficial Ownership

Statement of changes in beneficial ownership of securities
Jul 02, 2019

Statement Of Changes In Beneficial Ownership

Statement of changes in beneficial ownership of securities
Jul 02, 2019

Statement Of Changes In Beneficial Ownership

Statement of changes in beneficial ownership of securities
Jun 11, 2019

Beneficial Ownership Change

Statement of acquisition of beneficial ownership by individuals
May 23, 2019

Major Issues Report

Current report, item 3.01
May 14, 2019

Quarterly Report

Quarterly report [Sections 13 or 15(d)]
May 14, 2019

Major Issues Report

Current report, items 2.02 and 9.01
May 23, 2017

Major Issues Report

KEMPHARM公司